Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction of Murepavadin and Colistin in Healthy Subjects
NCT02156323Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of murepavadin in Pseudomonas aeruginosa infection (2 arms), sponsored by Roche. Primary endpoint: Multiple dose pharmacokinetics of RO7033877 and colistin/CMS: Cmax and AUC up to 4 days. Started Jul 2014; status: completed.
02
Drugs
murepavadin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT02156323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156323.